SCHEMBL856837

SCHEMBL856837

Nc1ncc(Br)cc1S(=O)(=O)NCC(O)CO

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.52
PLA2G1B P04054 1/20 0.52
ATG4B Q9Y4P1 1/20 0.52
MEN1 O00255 7/20 0.49
KMT2A Q03164 7/20 0.49
GAA P10253 2/20 0.47
MAPT P10636 2/20 0.47
RAB9A P51151 1/20 0.47
SHMT2 P34897 1/20 0.46
HSD17B10 Q99714 2/20 0.46
ALDH1A1 P00352 2/20 0.46
NPY1R P25929 1/20 0.45
NPY2R P49146 1/20 0.45
LMNA P02545 1/20 0.45
GFER P55789 1/20 0.45
ALOX5AP P20292 1/20 0.44
FEN1 P39748 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL855353 0.85 NPC1 (0.56) NPC1PLA2G1BATG4BMEN1KMT2A
SCHEMBL6126140 0.84 ALOX5AP (0.40) NPC1PLA2G1BATG4BMEN1KMT2A
SCHEMBL27851665 0.84 MEN1 (0.50) NPC1PLA2G1BATG4BMEN1KMT2A
SCHEMBL856328 0.82 PLA2G1B (0.59) NPC1PLA2G1BATG4BMEN1KMT2A
SCHEMBL742729 0.81 ALDH1A1 (0.57) NPC1PLA2G1BATG4BMEN1KMT2A
SCHEMBL858360 0.80 KMT2A (0.46) NPC1PLA2G1BATG4BMEN1KMT2A
SCHEMBL858026 0.80 NPC1 (0.43) NPC1PLA2G1BATG4BMEN1KMT2A
SCHEMBL27868741 0.79 HSD17B10 (0.47) NPC1PLA2G1BATG4BMEN1KMT2A
SCHEMBL741550 0.78 KMT2A (0.54) NPC1PLA2G1BATG4BMEN1KMT2A
SCHEMBL858850 0.77 NPC1 (0.59) NPC1PLA2G1BATG4BMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-04-17 US disclosed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
EP-2640366-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE Exelixis, Inc. (US) 2013-09-25 EP disclosed
WO-2012068096-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE EXELIXIS, INC. (US) 2012-05-24 WO disclosed
EP-2432779-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2012-03-28 EP disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
WO-2010135524-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA NPC1 1583/4885PLA2G1B 2233/4885ATG4B 739/4885
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA NPC1 1273/4885PLA2G1B 2818/4885ATG4B 692/4885
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA NPC1 1132/4885PLA2G1B 2230/4885ATG4B 677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.